# VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

> **NCT04725877** · PHASE1 · COMPLETED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 27 (actual)

## Conditions studied

- HIV I Infection

## Interventions

- **BIOLOGICAL:** VIR-1111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04725877
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2022-12-05
- **Final completion:** 2022-12-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725877, "VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04725877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*